SPONSORED CONTENT Whether it’s new manufacturer restrictions affecting script and data qualification, amended state laws or regulations, or updated audit […]
SPONSORED CONTENT When it comes to doing more with less, Community Health Centers (CHCs) and Federally Qualified Health Centers (FQHCs) […]
SPONSORED CONTENT The U.S. drug pricing infrastructure is entering a transformative era. On August 1, 2025, the Health Resources and […]
SPONSORED CONTENT Federally Qualified Health Centers (FQHCs) play a critical role in delivering accessible and affordable healthcare to underserved communities. […]
SPONSORED CONTENT The 340B program has morphed into a battlefield of rules, audits, and reporting. For smaller covered entities (CEs), […]
SPONSORED CONTENT Since this article was published, HRSA released new guidance on a proposed pilot rebate model. This pilot would […]
SPONSORED CONTENT The regulatory landscape for the 340B drug pricing program is evolving rapidly. As scrutiny from the Health Resources […]
SPONSORED CONTENT AI is everywhere—chatbots, smart assistants, predictive tools. But in 340B? The line between what’s useful and what’s just […]
SPONSORED CONTENT Introduction: Navigating Political Headwinds As the 2025 political season heats up, federally qualified health centers (FQHCs), hospitals, STD […]
SPONSORED CONTENT Let’s be honest. 340B compliance is demanding. It takes time, coordination, and precision. After more than a decade […]